Core Insights - ModeX Therapeutics Inc., a subsidiary of OPKO Health, has entered into a collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies targeting various therapeutic areas [1][2][3] Financial Terms - ModeX will receive an upfront payment of USD $7 million, with potential future payments exceeding USD $200 million per selected molecule, and the overall collaboration value could exceed $1 billion if multiple products succeed [2][8] - ModeX is also eligible for tiered global net sales royalties, reaching up to low double digits at the highest tier [2] Collaboration Details - The partnership aims to leverage ModeX's MSTAR platform and Regeneron's proprietary binders to create multispecific antibody candidates that can target multiple biological pathways [1][4] - Regeneron will lead and fund all preclinical and clinical development activities for the products advanced under this collaboration [2][4] Scientific Innovation - ModeX's MSTAR platform enables the development of multispecific antibodies that can address multiple disease pathways simultaneously, which is crucial for treating complex conditions [5] - The collaboration is expected to enhance the therapeutic potential of antibodies in areas such as immunology, oncology, and metabolic diseases [3][4] Company Background - ModeX Therapeutics is focused on developing innovative multispecific biologics for cancer and infectious diseases, with a pipeline that includes candidates for solid and hematologic tumors [6] - OPKO Health is a multinational biopharmaceutical and diagnostics company aiming to establish leading positions in rapidly growing markets through its proprietary technologies [9]